Review of cancer drugs for treating early or advanced HER2-positive breast cancer

Published on 12 Jul 2022
Last Updated on 01 Sep 2023

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended listing pertuzumab, pertuzumab plus trastuzumab fixed-dose subcutaneous (SC) injection, trastuzumab emtansine or tucatinib on the Medication Assistance Fund (MAF) for treating human epidermal growth factor receptor (HER2)-positive breast cancer due to unfavourable cost-effectiveness at the prices proposed by the manufacturer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Review of cancer drugs for treating early or advanced HER2-positive breast cancer (Updated 1 Sep 23) [PDF, 168 KB]

Treatments for HER2-positive breast cancer PES (12 Jul 22) [PDF, 91 KB]